0001562180-24-004011.txt : 20240514 0001562180-24-004011.hdr.sgml : 20240514 20240514073029 ACCESSION NUMBER: 0001562180-24-004011 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240513 FILED AS OF DATE: 20240514 DATE AS OF CHANGE: 20240514 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CHILDS JOHN W CENTRAL INDEX KEY: 0001027035 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41477 FILM NUMBER: 24941454 MAIL ADDRESS: STREET 1: 111 HUNTINGTON AVENUE STREET 2: SUITE 2900 CITY: BOSTON STATE: MA ZIP: 02199 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Biohaven Ltd. CENTRAL INDEX KEY: 0001935979 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 FORMER COMPANY: FORMER CONFORMED NAME: Biohaven Research Ltd. DATE OF NAME CHANGE: 20220629 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-05-13 false 0001935979 Biohaven Ltd. BHVN 0001027035 CHILDS JOHN W C/O BIOHAVEN LTD. 215 CHURCH STREET NEW HAVEN CT 06510 true false false false false Common Shares 2024-05-13 4 P false 28500.00 35.1744 A 2283341.00 I By John W Childs 2013 Revocable Trust Common Shares 24391.00 I By 1994 Charitable Remainder Trust Common Shares 4096512.00 I By 2021 B-H Charitable Remainder Trust The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.00 - $35.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. /s/ George Clark, Attorney-in-Fact 2024-05-14